Hepatitis C

The researchers found sero-protection rate at 12-month was significantly higher in the ID arm compared to the IM cohort.

Biologic use was not associated with an increased risk of hepatitis B virus flares.

More than 56% of these patients enrolled in TARGET-NASH were being treated with statins.

A maternal-infant HCV linkage program in combination with a multidisciplinary clinic to collocate mother and infant care was implemented in 2016.

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

Sustained virologic response following direct acting antiviral treatment substantially reduced the all-cause mortality rate in patients with HCV.

The expansion for sofosbuvir/velpatasvir is supported by phase 2 data showing an 83% sustained virologic response or cure rate among patients as young as 3 years old.

Direct-acting antivirals has increased the need to treat children HCV patients before they begin to engage in dangerous behaviors.

A recommendation for all adults in the US to be screened for HCV has increased the need for treatment programs in urban areas.

Data show low BMI, male gender, and older age in patients associated with higher overall mortality.

COVID-19 patients with liver injuries are at a higher risk of mortality or lengthier hospital stays.

Data show global burden of NAFLD increased, while burden of cirrhosis decreased in adolescents and young adults.

Data show males, patients with high BMI correlated with higher FAST score in HCV care.

A large proportion of HCV patients remain undiagnosed, particularly in the older population.

Incidence rates decreased by nearly half after direct-acting antiviral treatment regimen.

An electronic reminding system helped identify 3783 patients with anti-HCV antibody documentation.

The majority of adverse effects reported were considered mild.

The CDC currently recommends every pregnant woman screened for hepatitis C virus.

New data affirms a low rate of hepatitis B vaccination responsiveness among patients with hepatitis B core antibodies.

The study authors said that decentralizing dispensation of hepatitis C treatment re-engages patients.

There is a need for cost-effective treatments for HCV in low-income countries.

Direct-acting antivirals have been a major milestone in the treatment of hepatitis C virus, new data show they also work in nearly all children, without serious adverse events.

Raising awareness about proper treatment adherence is one method of working toward eliminating hepatitis C.

More than 90% of patients with hepatitis C who sought care at a comprehensive community health clinic completed treatment, and three-quarters of those returned for sustained virologic response testing.

“[sCD163] showed a significant decline in eradicated cases of HCC after treatment,” the study authors wrote.

There were no drug-related serious adverse events found in the study.

Treatment use was linked to an increase in hepatitis B flare among women, but not men.

Most patients who were treated with direct-acting antivirals for hepatitis C virus infection saw improvement in oral lichen planus symptoms, including 6 of 10 who saw complete remission.

Individuals with malnutrition had higher mortality rates, as well as higher rates of sepsis and pneumonia.

The investigators monitored any retinopathy events in hepatitis C patients, including those that were untreated and those being treated with PegIFN/RBV.